Insights On Upstream Manufacturing

  1. LNP-Mediated Cell Transfection In Bioreactors Across Workflows 6/24/2026

    Lipid nanoparticles are redefining immune cell engineering. Delve into new data that demonstrates the performance across multiple cell types and bioreactor systems, supporting their potential workflows.

  2. Enhancing Host Cell DNA Testing With Digital PCR 6/24/2026

    Residual host cell DNA testing is evolving with digital PCR. Discover how streamlined methods improve accuracy, minimize manual steps, and support efficient biopharmaceutical manufacturing processes.

  3. A Clear Path To Rapid, Consistent Biosimilar Development 6/23/2026

    Faster timelines don’t have to come at the expense of quality or consistency. Discover proven strategies to generate stable, high-performing cell lines while reducing risk and supporting reliable scale-up.

  4. Filtration In Preparation Of Cell Culture Media And Buffers 6/22/2026

    Refine media and buffer prep with filtration that removes particles, reduces bioburden, and safeguards sterility — protecting processes, preventing contamination, and consistent biopharma performance.

  5. How Intensified Upstream Processing Improves Scale-Up And Tech Transfer 6/22/2026

    Intensified upstream processing can improve scalability and maintain quality. Learn how automation, PAT, and data-driven control strategies help modernize workflows and support consistent performance.

  6. From Process Monitoring To Manufacturing Intelligence: Real-Time Analytics And Predictive Control In Biomanufacturing 6/19/2026

    Advanced analytics, predictive modeling, explainable AI, and digital twins are helping biomanufacturers improve process visibility, anticipate outcomes, and support smarter operational decisions.

  7. Towards A Universal LNP Platform For Multiplex Engineering 6/19/2026

    Multiplex engineering of T cells for solid tumors requires precise delivery. Emerging LNP approaches enable co-delivery of RNA and DNA, offering a safer, more scalable path beyond viral vectors.

  8. Extrahepatic Delivery Of mRNA-LNP To Spleen 6/19/2026

    In vivo CAR-T approaches aim to reprogram T cells directly in the body using targeted lipid nanoparticles. Improved delivery to immune organs highlights new potential for scalable cell therapies.

  9. Discover A System That Can Be Used With Various Cell Culture Media 6/19/2026

    Evolving CAR T cell therapies are raising the bar for manufacturing. Advances in cell expansion and the shift to serum-free media are redefining how scalable, future-ready processes are designed.

  10. Developing CAR T Therapies With A Cell Therapy Manufacturing Platform 6/19/2026

    Advances in CAR T cell engineering are expanding clinical potential, but manufacturing complexity limits scale. Integrated, automated workflows offer a path to consistent and efficient production.